Randomised feasibility trial of an onward HIV disclosure intervention

  • Research type

    Research Study

  • Full title

    Randomised feasibility trial of an onward HIV disclosure intervention for 18-25 year olds living with perinatally acquired HIV

  • IRAS ID

    252582

  • Contact name

    Michael Evangeli

  • Contact email

    michael.evangeli@rhul.ac.uk

  • Sponsor organisation

    Royal Holloway University of London

  • ISRCTN Number

    ISRCTN31852047

  • Clinicaltrials.gov Identifier

    N/A, N/A

  • Duration of Study in the UK

    2 years, 6 months, 1 days

  • Research summary

    There are large numbers of young people with HIV globally, many with perinatally acquired HIV (PAH). Young people with PAH face challenges in adhering to antiretroviral therapy (ART), managing onward HIV transmission risk, and maintaining wellbeing. Onward HIV disclosure (sharing one’s HIV status with others) may facilitate positive outcomes in the above areas. Sharing of one’s HIV status with sexual partners may decrease HIV transmission risk through more consistent condom use, or the use of pre and post-exposure prophylaxis, if virally non-suppressed. Onward disclosure may also facilitate ART adherence and improve well-being. Despite the public health and individual benefits of onward disclosure, there are low rates of onward disclosure in young people with PAH. No interventions have been developed to support this population to make decisions about sharing their status, and there is a lack of onward disclosure guidance for this population or for professionals working with them.

    This study aims to develop and test the feasibility of a behavioural intervention to increase onward disclosure levels and support onward disclosure decision-making in perinatally infected 18-25 year olds in the UK and Uganda. We will:
    • Develop the planned intervention for each context (Phase 1: 12 months, n=50).
    • Conduct a randomised feasibility parallel group trial of the intervention alongside a standard of care condition (Phase 2 main study: 18 months). A sample size of 64 per condition (intervention or standard of care) (128 participants in total: 32 in each condition in each country) with data at both the baseline and follow-up time points, across UK and Ugandan sites will be recruited. We will recruit additional participants at baseline to allow for attrition (30 per country, i.e., a total of 188 participants). Face to face interviews with ten participants in the UK and ten participants in Uganda will also be conducted(Phase 2 sub-study).

  • REC name

    London - Brent Research Ethics Committee

  • REC reference

    18/LO/1810

  • Date of REC Opinion

    9 Jan 2019

  • REC opinion

    Further Information Favourable Opinion